For Healthcare Professionals Login to the Nplate® NEXUS Program
About Nplate™NEXUS
What Is the Nplate™ (romiplostim) NEXUS Program?
Nplate™ is only available through the Nplate™ NEXUS (Network of Experts Understanding and Supporting Nplate™ and patients) Program. This program is designed to promote informed risk-benefit decisions before initiating treatment and while patients are on treatment to assure appropriate use of Nplate™ in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate™ should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts. Nplate™ is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP.

The Nplate™ NEXUS Program consists of a patient registry and a requirement for prescribers to complete baseline and periodic safety information for every patient. As a prescriber, you must enroll in the Nplate™ NEXUS Program in order to prescribe Nplate™ by completing the Nplate™ NEXUS Program Healthcare Provider Enrollment Form. Prescribers are required to comply with the following program requirements:

  • Read the full prescribing information for Nplate™.
  • Understand the approved indication.
  • Understand that Nplate™ should not be used in an attempt to normalize platelet counts.
  • Understand that Nplate™ is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.
  • Understand the risks associated with Nplate™.
  • Understand that each patient should be monitored to assure safe use of Nplate™.
  • Understand how to properly dose and administer Nplate™ in order to prevent
    medication errors.
  • Understand that you must complete this Nplate™ NEXUS Program Healthcare Provider Enrollment Form to enroll in the Nplate™ NEXUS Program (only enroll once).
  • Enroll each patient by completing the Nplate™ NEXUS Patient Enrollment Form and Nplate™ NEXUS Program Patient Baseline Data Form. Complete the Nplate™ NEXUS Program Patient Baseline Data Form at the time of enrollment or within 30 days of patient enrollment. Baseline data is only to be used to assess for risk factors for adverse events and to evaluate the long-term safety of Nplate™.
  • Provide each patient with the Nplate™ Medication Guide prior to each dose and counsel each patient on the risks and benefits of Nplate™.
  • (1) Complete the Nplate™ NEXUS Patient Enrollment Form for each patient,
    (2) obtain patient's signature authorizing disclosure of health information related to the Nplate™ NEXUS Program, and
    (3) send the completed Nplate™ NEXUS Program Patient Enrollment Form to the Nplate™ NEXUS Program for patient enrollment.
  • Counsel each patient to carry a Patient ID Card and Dosing Tracker that identifies the risks with Nplate™ and contains the Nplate™ NEXUS Program access number.
  • Evaluate the safe use and patient status every 6 months to determine whether the patient should continue Nplate™ and if so, authorize treatment for another 6 months.
  • Notify the Nplate™ NEXUS Program when a patient discontinues Nplate™ by completing the Nplate™ NEXUS Program Patient Discontinuation Form/Post-Discontinuation Follow-Up Form at the time of Nplate™ discontinuation and 6 months later.
  • Promptly report to the Nplate™ NEXUS Program any adverse events occurring in the
    course of the use of the drug as described in the Nplate™ NEXUS Program Patient
    Safety Questionnaire.
  • Understand that Amgen will be regularly evaluating compliance with the Nplate™ NEXUS Program, and that Amgen reserves the right to restrict your ability to enroll future patients or take other appropriate measures at any time if you fail to comply with Nplate™ NEXUS Program requirements.